Navigation Links
Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux
Date:10/5/2009

ROCHESTER, N.Y., Oct. 5 /PRNewswire/ -- Bausch & Lomb, the global eye health company, today announced it has acquired the commercial assets of Tubilux Pharma S.p.A.

Tubilux is a privately held ophthalmic pharmaceuticals company that develops and markets a range of proprietary, over-the-counter, and branded generic products primarily in Italy, and with distribution in approximately 30 other countries.

Under the terms of the agreement, Bausch & Lomb has acquired the company's ophthalmic pharmaceuticals portfolio, as well as its commercial and sales operations. Group Tubilux will retain its manufacturing operation, producing existing products for Bausch & Lomb under a multi-year contract.

"This agreement more than doubles our presence in the Italian ophthalmic pharmaceuticals market," said Charl van Zyl, head of Bausch & Lomb's Pharmaceuticals business for Europe, Middle East and Africa. "Bausch & Lomb is committed to expanding our portfolio offerings, and we believe that this investment will prove successful for the company, doctors and patients alike."

The acquired Tubilux portfolio includes products for dry eye relief (Oxyal, Lipimix, and Vitadrop); for glaucoma (Cebrolux and Timolux); for anti-infective use (Oftaquix); and for anti-inflammatory use (Fluaton).

"As a result of this transaction, Tubilux will strengthen its focus and presence in the ophthalmic pharmaceutical contract manufacturing sector, including ointments, gels and eye drop formats," said Emidio Fedeli, chief executive officer of Group Tubilux.

Sal Oppenheim Jr. & Cie. KGaA Milan Branch acted as the sole financial advisor of Group Tubilux in this transaction.

Financial terms of the agreement will not be made public.

About Bausch & Lomb

Bausch & Lomb is dedicated to bringing visionary ideas to eye health. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. The Bausch & Lomb name is one of the best-known and most respected healthcare brands in the world. Founded in 1853, the company is headquartered in Rochester, N.Y., and employs more than 10,000 people worldwide. Its products are available in more than 100 countries. More information is available at www.bausch.com.

SOURCE Bausch & Lomb


'/>"/>
SOURCE Bausch & Lomb
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
2. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
3. Sigma-Aldrich (Nasdaq: SIAL) Announces Appointment of George Miller as Sr. Vice President, General Counsel & Secretary
4. Robbins & Myers Announces Regular Quarterly Cash Dividend
5. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
6. Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year
7. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
8. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
9. U.S. Preventive Medicine Acquires Specialty Disease Management
10. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
11. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... 2016 Hutchison China MediTech ... on the highly lucrative global oncology and immunology ... potential first-in-class or best-in-class tyrosine kinase inhibitor (TKI) ... strategic partners. HCM,s profitable Chinese healthcare business continues ... expect progress of the mid-to-late-stage pipeline during 2016-17 ...
(Date:5/27/2016)... , May 27, 2016 Amarantus ... focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, ... will be presenting at two upcoming investor conferences: ... 730 Third Avenue, New York City , NY ... Marcum MicroCap Conference   Where: Grand ...
(Date:5/26/2016)... 26, 2016 According to a new ... Market - U.S. Industry Analysis, Size, Share, Growth, Trends, and ... the U.S. was valued at US$ 5.89 Bn in 2014 ... from 2015 to 2023 to reach US$ 7.99 Bn in ... and emerging needle free drug delivery devices and the market ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... An educational ... by inspiring human-interest stories, courtesy of awareness-driven celebrities and thought leaders. It also ... advocates, associations and industry leaders such as Bioness. , As patients feel ...
(Date:5/27/2016)... ... 2016 , ... Aimed at nurses and employees in the health care world, ... in the nursing and health care industry. It also provides insight to the developing ... , As the nursing industry is coming out of one of the biggest ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways to ... Sausage Council (NHDSC) suggests that Americans prefer their dogs straight off the grill. Of ... grilling is their favorite way to cook a hot dog, far outpacing other cooking ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... (IP) to its specialty academic programs. , Answering to the increasing demand for ... programs in health law, and environmental and land use law. ,  , “The ...
(Date:5/26/2016)... Pittsburgh, PA (PRWEB) , ... May 26, 2016 ... ... transplantation, and one that has a significant negative impact on long-term patient survival, ... to date. The results, published online this week in the Journal of Thoracic ...
Breaking Medicine News(10 mins):